The emergence of pure chemical protein synthesis as a commercially viable method of drug design and production will create serious problems in the patent system.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hancock, W.S. et al. J. Bio. Chem. 247, 6224 (1972).
Warren, J.D. et al. J. Am. Chem. Soc. 126, 6576 (2004).
Kent, S.B.H. et al. Science 299, 884 (2003).
Kent, S.B.H. et al. Science 266, 776 (1994).
Burnham, N.L. Amer. J. Hosp. Pharm. 51, 210 (1994).
Hudecz, F. in Self-Assembling Peptide Systems in Biology, Medicine and Engineering (ed. Aggeli, A. et al.) 139–140 (Kluwer Academic Publishers, Dordrecht, Netherlands, 2001).
Kochendoerfer, G.G. et al. Science 299, 884 (2003).
US Patent No. 6,806,065 (Oct. 19, 2004) (claiming inter alia “an isolated nucleic acid molecule encoding a Rickettsia felis outer membrane protein”).
US Patent No. 6,800,473 (Oct. 5, 2004) (claiming inter alia human cathepsin L2 protein and its coding gene).
US Patent No. 6,794,500 (Sept. 21, 2004) (claiming RNA-binding protein).
Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 (Fed. Cir.), cert. denied, 502 US 856 (1991).
US Patent No. 6,057,434 (May 2, 2000).
US Patent No. 5,880,263 (Mar. 9, 1999).
Demaine, L.J. & Fellmeth, A.X. Stanford Law Rev. 55, 303, 357 (2002).
35 USC § 103 (2004).
US Patent No. 6,797,814 (Sept. 28, 2004).
US Patent No. 6,476,190 (Nov. 5, 2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fellmeth, A. The challenge to patent law of pure chemical protein synthesis. Nat Biotechnol 23, 547–549 (2005). https://doi.org/10.1038/nbt0505-547
Issue Date:
DOI: https://doi.org/10.1038/nbt0505-547
